Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antidepressant Efficacy of Mlc901 in the 6-Hydroxydopamine Mice Model of Parkinson’S Disease Publisher



Ebrahimighiri M1 ; Alijanpour S2 ; Khakpai F3 ; Zarrindast MR4, 5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Faculty of Sciences, University of Zanjan, Zanjan, Iran
  2. 2. Department of Biology, Faculty of Science, Gonbad Kavous University, Gonbad Kavous, Iran
  3. 3. Cognitive and Neuroscience Research Center (CNRC), Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  4. 4. Department of Pharmacology School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Neuroendocrinology, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Physiology and Pharmacology (Iran) Published:2021


Abstract

Introduction: Depression is a common mood disorder in patients with Parkinson’s disease (PD), which negatively influences the quality of life and enhances caregiver burden. MLC901, a traditional medicine, has been demonstrated to be useful in preclinical and clinical studies. The aim was to study the effect of MLC901 on depression behavior in a mouse model of PD, comprising in the unilateral striatal delivery of the neurotoxin 6-hydroxydopamine (6-OHDA). Methods: Female NMRI mice were divided into the following groups: Sham/saline group, 6-OHDA/saline group, sham/MLC901 (40μg/kg) group and 6-OHDA/MLC901 group. Intraperitoneal treatments of MLC901 were started one week after the stereotaxic surgery that continued for 4 weeks (5 days/week). Locomotion was monitored using an openfield test and depressive-like responses were measured by forced swim test (FST) and tail suspension test (TST). Results: We found that MLC901 prevented the increased immobility time in the PD mice in both FST and TST, suggesting an antidepressant efficacy for the MLC901. None of the treatments alter locomotion compared to the sham group. Conclusion: In conclusion, we propose that MLC901 is a potential candidate to be used in studies for the treatment of depression in PD. © 2021, Iranian Society of Physiology and Pharmacology. All rights reserved.
Related Docs
View other Related Docs
1. Mlc901 During Sleep Deprivation Rescues Fear Memory Disruption in Rats, Naunyn-Schmiedeberg's Archives of Pharmacology (2019)
2. A Possible Neuroprotective Property of Ethanol And/Or Neuroaid on the Modulation of Cognitive Function, Neurotoxicology and Teratology (2020)
3. Effect of Cholestasis and Neuroaid Treatment on the Expression of Bax, Bcl-2, Pgc-1Α and Tfam Genes Involved in Apoptosis and Mitochondrial Biogenesis in the Striatum of Male Rats, Metabolic Brain Disease (2020)
Other Related Docs
4. The Neuroprotective Effect of Neuroaid on Morphine-Induced Amnesia With Respect to the Expression of Tfam, Pgc-1Α, Δfosb and Cart Genes in the Hippocampus of Male Wistar Rats, Gene (2020)
5. The Effect of Urb597, Exercise or Their Combination on the Performance of 6-Ohda Mouse Model of Parkinson Disease in the Elevated Plus Maze, Tail Suspension Test and Step-Down Task, Metabolic Brain Disease (2021)
6. High Angular Resolution Diffusion Imaging Correlates of Depression in Parkinson’S Disease: A Connectometry Study, Acta Neurologica Belgica (2018)